Median rwOS was 11.3 months (95% CI: 9.9–13.4) for the overall adenocarcinoma cohort with no actionable mutations, and 12.5 (95% CI: 9.9–17.9), 14.8 (95% CI: 10.5–19.4), and 9.1 (95% CI: 7.1–11.5) months for patients who received PD-1/PD-L1 inhibitor monotherapy, PD-1/PD-L1 inhibitor combination, and PBC combination, respectively (Table 4). This evidence concerns the gene CD274 and primary biliary cholangitis.